Clinical development

Samsung biosim nod sets J&J's Remicade up for tough fight Samsung Bioepis won FDA approval late Friday for its Remicade substitute, Renflexis (infliximab-abda), becoming the the second biosimilar to threaten that brand in the U.S. Not an unexpected event, and the launch isn’t expected until October because of bi...

Mammalian Target of Rapamycin (mTOR) is always in limelight for its wider application. It is a protein of a 289-kDa long chain contains serine and threonine kinase, and was first identified when rapamycin (Sirolimus) was discovered. mTOR helps in the synthesis of important cellular proteins which has a major impact ...

In United States, Ovarian Cancer has become the leading cause of death in women. Each year approximately 22,280 women are diagnosed with ovarian cancer, and out of those 14,240 die. Women with strong family history of breast cancer or ovarian cancer or who have tested positive for inherited mutation in BRCA1 or BRCA...